profit from every ₹100 of sales.
₹0₹100
Jubilant Pharmova
₹965.10-1.74% today
-11.2% in 1 year
1-year low ₹808.901-year high ₹1,087.40
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2023 to 2026.
0%20% a year
You pay ₹38.36 for every ₹1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Jubilant Pharmova sold, what it kept, and what it did with the cash.
Sales went from ₹62.2 billion in 2023 to ₹82.3 billion in 2026, with ₹3.99 billion of profit last year.
SalesProfit
Jubilant Pharmova vs. similar companies
Jubilant Pharmova grows in the middle of these 5 and is priced in the middle for its profits.
| Company | Profit from ₹100 of sales | Sales growth a year | Price per ₹1 of profit |
|---|---|---|---|
| Jubilant Pharmova | 38.4× · Expensive | ||
 Merck KGaA | 24.9× · Fair price | ||
 Takeda Pharmaceutical | 102.5× · Very expensive | ||
 Galderma Group | 86.9× · Very expensive | ||
 Teva Pharmaceutical Industries | 36.8× · Expensive |
AI analysis
An AI analyst reads Jubilant Pharmova's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| 62,193 | 66,448 | 71,921 | 82,250 | |
| 39,965 | 42,227 | 48,751 | 55,807 | |
| 2,299 | 5,231 | 8,051 | 8,194 | |
| 7,504 | 8,088 | 15,895 | 12,663 | |
| -610 | 771 | 8,394 | 3,985 | |
| -3.83 | 4.86 | 52.85 | – | |
| 64.3% | 63.5% | 67.8% | 67.9% | |
| 3.7% | 7.9% | 11.2% | 10.0% | |
| -1.0% | 1.2% | 11.7% | 4.8% |
Balance sheet
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Total assets | 111,567 | 115,485 | 127,564 | 155,227 |
| Cash | 10,108 | 9,539 | 10,862 | 12,671 |
| Total debt | 36,768 | 36,640 | 27,310 | 36,147 |
| Total liabilities | 57,649 | 61,274 | 65,178 | 84,271 |
| 53,993 | 54,339 | 62,549 | 70,928 | |
| 159 | 159 | 159 | – | |
| 1.7% | 3.7% | 10.7% | 6.1% | |
| -1.1% | 1.4% | 13.4% | 5.6% |
Cash flow
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| 6,607 | 9,713 | 10,721 | 12,268 | |
| 8,145 | 8,977 | 11,156 | 14,491 | |
| -1,538 | 736 | -435 | -2,223 | |
| Dividends paid | 801 | 798 | 796 | 795 |
| 40 | 274 | 56 | 187 | |
| 37 | 85 | 43 | 118 |
Valuation
- 38.4×
- –
- –
- 2.1×
- 1.9×
- –
- 13.9×
- -1.5%
- 2.6%
- 0.5%
Profitability
- 67.9%
- 10.0%
- 4.8%
- –
- 5.8%
- 5.3%
- –
- –
- –
- –
Growth
- +9.8%
- –
- –
- –
- −0.1%
Financial health
- 1.9×
- 0.51
- –
- 3.9×
- 1.62
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 49%of 952
Top 49%of 884
Bottom 32%of 601
Bottom 47%of 887
Bottom 31%of 987
0.5%of the share price, paid each year
On $1,000 invested$5a year at today's yield, before tax
–per share
Raised–not every year
How safe it looks
19.9% of its profit
Room to growStretchedMore than it earnsNews
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
28No pass
Benjamin Graham
30No pass
Philip Fisher
38No pass
Peter Lynch
52No pass
Joel Greenblatt
18No pass
Charlie Munger
27No pass
Terry Smith
24No pass
Questions about Jubilant Pharmova
Is Jubilant Pharmova a good stock to buy?
A business with weak numbers, but the price is high. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Jubilant Pharmova AI analysis
What does Jubilant Pharmova do?
Jubilant Pharmova Limited operates as an integrated pharmaceutical company in India, the Americas, Europe, and internationally. It is in Drug Manufacturers - Specialty & Generic, based in Noida, India.
Does Jubilant Pharmova pay a dividend?
Yes. At today's price the dividend is 0.5% a year, about 20% of its yearly profit. In 2026 it paid out ₹795 million in dividends.
Is Jubilant Pharmova stock halal?
Yes. Jubilant Pharmova passes our halal screen: its business is permitted and its debt is 24% of its market value, under the 30% limit. How we check
How has Jubilant Pharmova stock done over the past year?
Down 11.2% over the past twelve months, to ₹965.10. It traded between ₹808.90 and ₹1,087.40 and is 11.2% below its high.
Who are Jubilant Pharmova's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with Jubilant Pharmova's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.